PP_1170x120_10-25-21

Boehringer Ingelheim Pharmaceuticals

Boehringer Ingelheim’s Gilotrif approved for new indication

Boehringer Ingelheim’s Gilotrif approved for new indication

RIDGEFIELD, Conn. — After being granted a priority review from the Food and Drug Administration this past fall, Boehringer Ingelheim Pharmaceuticals Inc. has received approval of its supplemental New Drug Application (sNDA) for Gilotrif (afatinib), a lung cancer medication. Boehringer Ingelheim said Gilotrif is indicated for the first-line treatment of patients with metastatic non-small cell lung

Boehringer Ingelheim biosimilar Cyltezo OK’d by FDA

Boehringer Ingelheim biosimilar Cyltezo OK’d by FDA

RIDGEFIELD, Conn. —  Boehringer Ingelheim Pharmaceuticals Inc. has gained Food and Drug Administration approval for Cyltezo, a biosimilar of Humira from AbbVie Inc. Boehringer Ingelheim said Tuesday that Cyltezo (adalimumab-adbm) comes in a prefilled syringe and is indicated to treat a range of chronic inflammatory diseases, including moderate to severe active rheumatoid arthritis, moderate to

Lilly, BI cleared to market Basaglar long-acting insulin

Lilly, BI cleared to market Basaglar long-acting insulin

INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc. have received approval for Basaglar long-acting insulin (insulin glargine injection, 100 units/ml) in the United States. The companies said Basaglar has an identical amino acid sequence to Lantus, another U-100 insulin glargine, and is delivered via the prefilled Basaglar KwikPen. Basaglar

Adheris Health